Webcasts
Preparing biologics for commercialization: strategies to reduce risk and optimize outcomes
September 28th 2022Wednesday, September 28, 2022 at 10 AM EST | 4 PM CET Optimize your late-phase strategy to prepare your biologic for commercialization. CDMO experts share their time-tested best practices on how to adapt for uncertain market demand to get your drug to market on time.
The Ever-Changing World of Extractables and Leachables, Part 4, A Free Virtual Conference
May 18th 2022Wednesday, May 18th, 2022 at 3pm BST | 10am EDT | 4pm CEST | 7am PDTJoin global industry and regulatory experts as they discuss current E&L hot topics on pharmaceuticals, biopharmaceuticals and medical devices.
Industrializing High-Throughput Glycoproteomics Using AI for Clinical Use
April 26th 2022Aberrant glycosylation of proteins has been implicated in key steps of disease biology, including the hallmarks of cancer as well as inflammation cascades associated with autoimmunity and aging. InterVenn Biosciences harnesses the predictive powers of artificial intelligence combined with cutting edge mass spectrometry to discover clinically relevant biomarkers that can only be revealed by high-resolution analysis of the glycoproteome.
Oligonucleotide Purification and Characterization - Tips for Success
March 30th 2022Wednesday, March 30th, 2022 at 11am SST | 2pm AEDT | 10am ICT | 12pm KST Applying the appropriate tools for oligonucleotide purification and subsequent analysis is a unique challenge requiring application specific solutions. Join Drs. Anne Blackwell and Matthew L. Turner of Agilent Technologies for tips on oligonucleotide analysis and purification with Agilent’s suite of Bio LC solutions.
Glycomics/Glycoproteomics for Biopharmaceutical and Biotechnology Industries
March 16th 2022Wednesday, March 16th, 2022 at 11am SST | 2pm AEDT | 10am ICT | 12pm KST Please join us for a series of three intense investigations into the practicalities required to define, identify, and explore the functions of important biological molecules including glycans, monoclonal antibodies, and oligonucleotides. We outline cutting edge and mainstay analytic tools and protocols, with multiple case studies and practical examples from world leading experts.
Why Flexible End-to-End Solutions Succeed in BDS Handling
May 27th 2021*Thursday, May 27, 2021 at 11am EDT| 8am PDT| 4pm BST| 5pm CEST* Transportation of your bulk drug substance (BDS) from downstream to the fill/finish site might not be as simple as it sounds. Mostly geographically detached, each batch of BDS is filled into different primary packaging, frozen to sub-zero temperatures, stored, and shipped before it is then thawed and drained at the fill/finish site. *On Demand Until May 27, 2022*
Bridging the Digital Divide to Advance Bio/Pharma Manufacturing and Quality: A Technology Forum
May 25th 2021*Tuesday, May 25, 2021 at 10am EDT* The bio/pharma industry is turning to proven digital technologies used in other industries to plan, develop, and monitor manufacturing processes, as well as in quality, training, and regulatory oversight. In this event, experts discuss how artificial intelligence, remote monitoring, digital twins, and other technologies can be applied to modernize bio/pharma processes and systems. Lessons learned from the pandemic will be shared. *On Demand Until May 25, 2022*
